Om Pharma and Astrazeneca enter into Strategic Collaboration to Expand Presence in Respiratory and Immunology Fields in China

OM Pharma enters into a strategic collaboration agreement granting AstraZeneca the exclusive right to import and distribute the immunological therapy Broncho-Vaxom® for the prevention and treatment of respiratory tract infections in China (excluding Hong Kong, Macau, and Taiwan).

OM Pharma and AstraZeneca celebrated their strategic collaboration agreement today at a partnership signing ceremony in Shanghai.

The strategic collaboration agreement grants AstraZeneca the exclusive right to import, distribute and promote OM Pharma’s Broncho-Vaxom® (Bacterial Lysates - OM-85) in China (excluding Hong Kong, Macau, and Taiwan). Broncho-Vaxom® is a therapeutic agent that effectively prevents and treats recurrent or acute respiratory infections in adult and pediatric patients by boosting the host immunity. In China, recurrent respiratory tract infection is a common disease in pediatrics, with an incidence rate of about 20% ¹. The prevalence of COPD among people over 40 years old is 8.2% ².The acute exacerbation of COPD occurs about 0.5 to 3.5 times per year, and is an important factor in COPD deaths ³.

This long-term collaboration will fully leverage both parties’ expertise and provide more effective treatment options for patients in China. The safety profile and clinical benefits of Broncho-Vaxom® have been proven by a large body of clinical evidence^4-6. China ’Consensus of Management of Children with RRTI’ strongly recommends bacterial lysates as a cost-effective prevention of RRTI in children ⁷.

Josef Troxler, CEO of OM Pharma, commented: “Broncho-Vaxom® is one of OM Pharma’s flagship products. The product has been used for a long time in clinical settings for the prevention of respiratory infections and immunological conditions. This highly synergistic collaboration between OM Pharma and AstraZeneca will improve the accessibility of Broncho-Vaxom®, accelerate the product’s growth in the Chinese market, and further solidify OM Pharma’s lead in the field of respiratory diseases and immunological therapies.”

Michael Lai, General Manager of AstraZeneca China, said: “AstraZeneca has been deeply rooted in China for 27 years. Staying true to our patient-centric mission, we continue to focus our efforts on the therapeutic areas with the most urgent medical needs and on providing high quality medicines for patients. Respiratory & Immunology are key areas of focus for AstraZeneca China. We hope to broaden and deepen the market penetration of Broncho-Vaxom® to improve the health of more patients in need.”

This agreement marks yet another strategic collaboration with a global pharmaceutical company, demonstrating OM Pharma’s capacity to expand geographically. This further underlines OM Pharma‘s ability to become a world-leading biopharmaceutical company focused on improving the lives of patients with respiratory and inflammatory diseases around the world.